Market news

Taysha Gene Therapies (TSHA) has an average rating of buy and mean price target of $13, according to

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common s

Detailed price information for Taysha Gene Therapies Inc (TSHA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and outlining cash coverage into late 2028. See our latest analysis for Taysha Gene Therapies. Taysha Gene Therapies has seen its share price move around these updates, with a 19.05% 30 day share price return and a very large 1 year total shareholder return, while the 5 year total shareholder return...

Moby summary of Taysha Gene Therapies, Inc.'s Q2 2026 earnings call

Motley Fool Press Release.

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that

Company reports 100% response rate in Part A trial, completes pivotal dosing, and maintains $455.4 million cash position into 2028

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company’s common stock a

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. P

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commerc

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now. On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten public offering of 32.5 million of its common stock, priced at $6 per share. The offering also involved prepaid warrants to buy 833,333 shares […]

Nagendran Sukumar executed the sale under a pre-established Rule 10b5-1 trading plan, retaining 936,410 shares worth $5.94 million.